{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:11:07Z","timestamp":1792631467784,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.intimp.2024.112275","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T04:34:26Z","timestamp":1715920466000},"page":"112275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Increased serum interleukin-41 correlates with disease severity in myasthenia gravis"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8690-247X","authenticated-orcid":false,"given":"Zhouyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6253-6167","authenticated-orcid":false,"given":"Zhouao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5908-5094","authenticated-orcid":false,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112275_b0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112275_b0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2024.112275_b0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.intimp.2024.112275_b0020","article-title":"Environmental factors affecting the risk of generalization for ocular-onset myasthenia gravis: a nationwide cohort study","author":"Wang","year":"2023","journal-title":"QJM"},{"issue":"4","key":"10.1016\/j.intimp.2024.112275_b0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2024.112275_b0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2024.112275_b0035","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.112275_b0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2024.112275_b0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.112275_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2024.112275_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00240","article-title":"New approaches to targeting B Cells for Myasthenia Gravis therapy","volume":"11","author":"Huda","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2024.112275_b0070","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2024.112275_b0075","article-title":"Meteorin-like\/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: a comprehensive review of preclinical and clinical studies","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0080","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41401-020-00529-9","article-title":"Involvement of the secreted protein Metrnl in human diseases","volume":"41","author":"Miao","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.intimp.2024.112275_b0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2014.11.006","article-title":"METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages","volume":"156","author":"Ushach","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0090","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.4049\/jimmunol.1800435","article-title":"Meteorin-like\/Meteorin-\u03b2 is a novel immunoregulatory cytokine associated with inflammation","volume":"201","author":"Ushach","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cca.2022.11.021","article-title":"Increased serum IL-41 is associated with disease activity in rheumatoid arthritis","volume":"538","author":"Gong","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.intimp.2024.112275_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156026","article-title":"Elevated levels of Metrnl in rheumatoid arthritis: association with disease activity","volume":"159","author":"Zhang","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2024.112275_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.dci.2021.104289","article-title":"Meteorin-like\/Meteorin-\u03b2 upregulates proinflammatory cytokines via NF-\u03baB pathway in grass carp Ctenopharyngodon idella","volume":"127","author":"Wang","year":"2022","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0110","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0115","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized Myasthenia Gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2024.112275_b0120","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.intimp.2024.112275_b0125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12035-014-8985-1","article-title":"Intrathymic Tfh\/B cells interaction leads to ectopic GCs formation and anti-AChR antibody production: central role in triggering MG occurrence","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.intimp.2024.112275_b0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2024.112275_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1110499","article-title":"Inflammation and autoimmune myasthenia gravis","volume":"14","author":"Huda","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24676","article-title":"Decreased serum interleukin-41\/Metrnl levels in patients with Graves' disease","volume":"36","author":"Gong","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.intimp.2024.112275_b0145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12944-020-01404-6","article-title":"Characterization of the serum levels of Meteorin-like in patients with inflammatory bowel disease and its association with inflammatory cytokines","volume":"19","author":"Gholamrezayi","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.intimp.2024.112275_b0150","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/ecco-jcc\/jjz001","article-title":"The adipokine metrnl ameliorates chronic colitis in Il-10-\/- mice by attenuating mesenteric adipose tissue lesions during spontaneous colitis","volume":"13","author":"Zuo","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.intimp.2024.112275_b0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3343\/alm.2019.39.4.345","article-title":"The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases","volume":"39","author":"Gasparyan","year":"2019","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.intimp.2024.112275_b0160","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/14397595.2015.1091136","article-title":"Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients","volume":"26","author":"Qin","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2024.112275_b0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12883-021-02432-0","article-title":"Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study","volume":"21","author":"Xie","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.intimp.2024.112275_b0170","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.51706","article-title":"The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis","volume":"10","author":"Huang","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.intimp.2024.112275_b0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diabres.2019.02.026","article-title":"Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis","volume":"150","author":"El-Ashmawy","year":"2019","journal-title":"Diabet. Res. Clin. Pract."},{"key":"10.1016\/j.intimp.2024.112275_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231943","article-title":"Circulating levels of Meteorin-like protein in polycystic ovary syndrome: a case-control study","volume":"15","author":"Fouani","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.112275_b0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11882-011-0178-7","article-title":"T-cell subset regulation in atopy","volume":"11","author":"Jutel","year":"2011","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.intimp.2024.112275_b0190","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41423-021-00803-8","article-title":"Meteorin-\u03b2\/Meteorin like\/IL-41 attenuates airway inflammation in house dust mite-induced allergic asthma","volume":"19","author":"Gao","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.112275_b0195","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.924564","article-title":"Meteorin-like (METRNL) attenuates myocardial ischemia\/reperfusion injury-induced cardiomyocytes apoptosis by alleviating endoplasmic reticulum stress via activation of AMPK-PAK2 signaling in H9C2 cells","volume":"26","author":"Xu","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.intimp.2024.112275_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12060817","article-title":"Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker","volume":"12","author":"Zhou","year":"2023","journal-title":"Pathogens"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T14:05:32Z","timestamp":1735308332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924007951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"alternative-id":["S1567576924007951"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112275","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased serum interleukin-41 correlates with disease severity in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112275"}}